In the second- and third-line post-CDK4/6 inhibitor settings, elacestrant (Radius Health) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard-of-care endocrine therapy in a phase 3 trial of men and postmenopausal women with estrogen receptor (ER)-positive/HER2-negative metastatic breast cancer.
Elacestrant is the first oral selective ER degrader (SERD) to show such a benefit. Results of the randomized phase 3 trial,